Sakar Healthcare Limited — PPTs, 10-02-2026: Investor Presentation

Here's a concise, retail-friendly summary in the style of an equity analyst for Twitter:

**1. Business Performance:**

API-integrated Sakar Healthcare delivered strong Q3FY26 results. Its diversified model, driven by CDMO and own brand exports, is gaining momentum, with oncology emerging as a key growth engine.

**2. Growth Drivers or Strategy:**

Sakar strategically focuses on oncology for value creation, using its EU-GMP approved Bavla facility (integrated API & FDF). This targets higher margins and global expansion, aiming for 100+ overseas contracts in two years.

**3. Recent Developments:**

The oncology facility secured EU approval for Imatinib supply to Accord Healthcare UK. Sakar's portfolio expanded to 11 marketing authorizations across Europe and emerging markets, with 11 oncology dossiers already approved.

**4. Key Financial Metrics:**

Q3FY26 revenue surged 62% YoY to ₹70.34 Cr; PAT soared 126% YoY to ₹10.25 Cr. PAT margin hit 15%, and basic EPS climbed to ₹4.6.

**5. Management Commentary / Outlook:**

Management called Q3 a 'defining quarter,' noting operational discipline drove scale and profitability. Sakar is poised to commercialize anti-cancer products globally, emphasizing value-driven innovation for future growth.